Literature DB >> 22712027

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Andrew J Vickers1, Simon F Brewster.   

Abstract

Cancer is a growth process and it is natural that we should be concerned with how the routinely used marker of prostate cancer tumour burden - PSA - changes over time. Such change is measured by PSA velocity or PSA doubling time, described in general as "PSA kinetics". However, it turns out that calculation of PSA velocity and doubling time is far from straightforward. More than 20 different methods have been proposed, and many of these give quite divergent results. There is clear evidence that PSA kinetics are critical for understanding prognosis in advanced or relapsed prostate cancer. However, PSA kinetics have no value for men with an untreated prostate: neither PSA velocity nor doubling time have any role in diagnosing prostate cancer or providing a prognosis for men before treatment.

Entities:  

Year:  2012        PMID: 22712027      PMCID: PMC3375697          DOI: 10.1016/j.bjmsu.2011.08.006

Source DB:  PubMed          Journal:  Br J Med Surg Urol        ISSN: 1875-9742


  35 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

3.  Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.

Authors:  Zohar A Dotan; Fernando J Bianco; Farhang Rabbani; James A Eastham; Paul Fearn; Howard I Scher; Kevin W Kelly; Hui-Ni Chen; Heiko Schöder; Hedvig Hricak; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers; Cathee Till; Catherine M Tangen; Hans Lilja; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2011-02-24       Impact factor: 13.506

5.  Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.

Authors:  M Frank O'Brien; Angel M Cronin; Paul A Fearn; Caroline J Savage; Brandon Smith; Jason Stasi; Peter T Scardino; Gabrielle Fisher; Jack Cuzick; Henrik Møller; R Timothy Oliver; Daniel M Berney; Christopher S Foster; James A Eastham; Andrew J Vickers; Hans Lilja
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

6.  Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

Authors:  H Ballentine Carter; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

7.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Authors:  Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Timothy Donahue; Leo Kusuda; Wade Sexton; Keith O'Reilly; Javier Hernandez; Andrew Chung; Douglas Soderdahl
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.

Authors:  David Palma; Scott Tyldesley; Paul Blood; Mitchell Liu; James Morris; Tom Pickles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-01       Impact factor: 7.038

10.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

View more
  27 in total

Review 1.  Conceptualizing prognostic awareness in advanced cancer: a systematic review.

Authors:  Allison J Applebaum; Elissa A Kolva; Julia R Kulikowski; Jordana D Jacobs; Antonio DeRosa; Wendy G Lichtenthal; Megan E Olden; Barry Rosenfeld; William Breitbart
Journal:  J Health Psychol       Date:  2013-10-24

2.  Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.

Authors:  Luciano Castiello; Marianna Sabatino; Jiaqiang Ren; Masaki Terabe; Hanh Khuu; Lauren V Wood; Jay A Berzofsky; David F Stroncek
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

3.  Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in California.

Authors:  David J Press; Salma Shariff-Marco; Daphne Y Lichtensztajn; Diane Lauderdale; Adam B Murphy; Pushkar P Inamdar; Mindy C DeRouen; Ann S Hamilton; Juan Yang; Katherine Lin; Donald Hedeker; Christopher A Haiman; Iona Cheng; Scarlett Lin Gomez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-30       Impact factor: 4.254

4.  Elevated CEA with negative PET scan on surveillance of colorectal cancers-a role of CEA kinetics.

Authors:  Anand Ebin Thomas; Mufaddal Kazi; Sanket Bankar; Smruti Mokal; Archi Agarwal; Ventakesh Rangarajan; Ashwin Desouza; Avanish Saklani
Journal:  Langenbecks Arch Surg       Date:  2021-10-16       Impact factor: 3.445

5.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797

Review 6.  Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

Authors:  Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

7.  Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.

Authors:  Ajalaya Teyateeti; Achiraya Teyateeti; Gregory C Ravizzini; Guofan Xu; Chad Tang; Shi-Ming Tu; Homer A Macapinlac; Yang Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

Review 8.  [Rational imaging of metastasized tumor diseases].

Authors:  H J Stemmler; M Schlemmer; S Reilich
Journal:  Internist (Berl)       Date:  2013-07       Impact factor: 0.743

9.  Personalized management in low-risk prostate cancer: the role of biomarkers.

Authors:  Siebren Dijkstra; Agus Rizal A H Hamid; Gisèle H J M Leyten; Jack A Schalken
Journal:  Prostate Cancer       Date:  2012-12-13

10.  Microarray-based identification of individual HERV loci expression: application to biomarker discovery in prostate cancer.

Authors:  Philippe Pérot; Valérie Cheynet; Myriam Decaussin-Petrucci; Guy Oriol; Nathalie Mugnier; Claire Rodriguez-Lafrasse; Alain Ruffion; François Mallet
Journal:  J Vis Exp       Date:  2013-11-02       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.